Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YMN-A02 in Advanced Primary Liver Cancer
NCT07580261Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of YMN-A02 in hepatocellular carcinoma (HCC) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Dose-Limiting Toxicity. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
YMN-A02
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07580261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07580261.